EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSLAFG00000008343
Gene Symbol: WEE1
2 External references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSLAFG00000002384
Gene Symbol: YES1
2 External references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSLAFG00000007735
Gene Symbol: ACHE
2 External references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Like Type 1

Ensembl ID : ENSLAFG00000008019
Gene Symbol: ACVRL1
2 External references
353 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Type 2b

Ensembl ID : ENSLAFG00000001488
Gene Symbol: ACVR2B
2 External references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A1 Receptor

Ensembl ID : ENSLAFG00000001262
Gene Symbol: ADORA1
2 External references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2a Receptor

Ensembl ID : ENSLAFG00000012109
Gene Symbol: ADORA2A
2 External references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A3 Receptor

Ensembl ID : ENSLAFG00000004812
Gene Symbol: ADORA3
2 External references
89 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Deaminase

Ensembl ID : ENSLAFG00000003020
Gene Symbol: ADA
2 External references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1a

Ensembl ID : ENSLAFG00000000055
Gene Symbol: ADRA1A
2 External references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1b

Ensembl ID : ENSLAFG00000016171
Gene Symbol: ADRA1B
2 External references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 2a

Ensembl ID : ENSLAFG00000002225
Gene Symbol: ADRA2A
2 External references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).